<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428762</url>
  </required_header>
  <id_info>
    <org_study_id>0100-18-ASF</org_study_id>
    <nct_id>NCT04428762</nct_id>
  </id_info>
  <brief_title>Glycemic Control and Quality of Life With i- Port Advance in Pediatric T1DM</brief_title>
  <official_title>Glycemic Control and Quality of Life With i- Port Advance in Pediatric T1DM: Multi Center Crossover and Prospective Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaplan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of T1DM in children, especially infants under 4 years of age, is increasing in&#xD;
      the last decade. Not all patients are willing or able, from different reasons, to be treated&#xD;
      with insulin pumps. This portion of patients' needs subcutaneous insulin injections, at lest&#xD;
      4 injections per day, sometimes up to 8 injections per day.&#xD;
&#xD;
      The recommended treatment is insulin injection before each carbohydrate content meal. Since&#xD;
      each injection may lead to pain, many patients do not inject all recommended doses. The&#xD;
      solution could be: eat with no bolus, or not to correct glucose level to retrain from pain&#xD;
      sensation. I-Port use is able to address this issue by reducing the pain sensation&#xD;
      accompanied with the injection. I-Port advance may give a technological solution to&#xD;
      non-insulin pump T1DM pediatric patients.&#xD;
&#xD;
      There are no reports in the literature of the use of iport in children and youth. This&#xD;
      information is essential since 95% of pediatric diabetes mellitus cases are insulin dependent&#xD;
      and require multiple injections. Better balanced diabetes in childhood may prevent&#xD;
      complications to long range and long-term diabetes therapy. Moreover, if discovered safe, the&#xD;
      iport can be used also for other subcutaneously delivered medication in children, such as&#xD;
      somtostatin analog, human growth hormone and clexane Study is designed as 2 parts. Initial&#xD;
      part is a cross over design to compare between ipor use an injections regarding glucose in&#xD;
      range, side effects and quality of life.&#xD;
&#xD;
      Second part is designed as prospective. To assess glycemic control with iport use or 3 months&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      study withdrawn Nor relevant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    we decided to change the protocol completely to an RCT.&#xD;
  </why_stopped>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a multi-center,2 parts study:&#xD;
the first part: randomized crossover study second part: prospective follow-up study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Life quality and satisfaction measures</measure>
    <time_frame>3 months from patient first enrollment</time_frame>
    <description>Life quality measure before and after I-Port Advance use by questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>3 months from patient first enrollment</time_frame>
    <description>Assessing Adverse effect while using I-port</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic control evaluation</measure>
    <time_frame>3 months from patient first enrollment</time_frame>
    <description>HbA1C% before and after 3 month use of I-port advance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>T1DM</condition>
  <arm_group>
    <arm_group_label>I-Port use arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular injection arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I-Port Advance use</intervention_name>
    <description>participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.</description>
    <arm_group_label>I-Port use arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with type 1 diabetes mellitus&#xD;
&#xD;
          2. Insulin injection â‰¥2 per day for at least a week.&#xD;
&#xD;
          3. Use of MDI insulin: Novorapid, Humalog or Apidra.&#xD;
&#xD;
          4. Ability and willingness to perform at least 3 daily self-measured plasma glucose&#xD;
             profiles&#xD;
&#xD;
          5. Ability and willingness to adhere to the protocol. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Insulin pump use&#xD;
&#xD;
          2. Mix insulin use -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

